AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
Biofrontera Inc. Common Stock
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG00HTD0PY9
0.79▲ 0.01 (1.04%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
—
Trailing P/E
—
Price / Sales
EV / Revenue
—
EV / EBITDA
—
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
—
Trading Information
Previous Close
0.78
Day's Range
0.78 – 0.81
52-Week Range
0.55 – 1.66
Volume
102.9K
Avg Volume
422.3K
Share Statistics
Shares Outstanding
Employees
94
Exchange
XNAS
Listed
2021-10-29
Share count as of August 11, 2026

Biofrontera Inc. Common Stock (BFRI) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Biofrontera Inc. Common Stock (BFRI)
What is Biofrontera Inc. Common Stock's Market Cap?
Biofrontera Inc. Common Stock's Market Cap is $11.7M, based on as-reported figures from SEC (XBRL) filings.
What is Biofrontera Inc. Common Stock's Price / Sales?
Biofrontera Inc. Common Stock's Price / Sales is 0.3×, based on as-reported figures from SEC (XBRL) filings.
What is Biofrontera Inc. Common Stock's Revenue (TTM)?
Biofrontera Inc. Common Stock's Revenue (TTM) is $46.2M, based on as-reported figures from SEC (XBRL) filings.
What is Biofrontera Inc. Common Stock's Net Income (TTM)?
Biofrontera Inc. Common Stock's Net Income (TTM) is -$6.4M, based on as-reported figures from SEC (XBRL) filings.
What is Biofrontera Inc. Common Stock's EBITDA?
Biofrontera Inc. Common Stock's EBITDA is -$6.4M, based on as-reported figures from SEC (XBRL) filings.
What is Biofrontera Inc. Common Stock's Diluted EPS (TTM)?
Biofrontera Inc. Common Stock's Diluted EPS (TTM) is -0.43, based on as-reported figures from SEC (XBRL) filings.
What is Biofrontera Inc. Common Stock's EBITDA Margin?
Biofrontera Inc. Common Stock's EBITDA Margin is -13.8%, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · BFRIAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Revenues, net
YoY growth+32.9%+17.4%+36.2%-22.5%
Operating expenses
Cost of Revenue————
Selling, General and Administrative Expense
Selling, general and administrative, related party
Patent remediation expense——
Research and Development Expense
Total operating expenses
% of revenue104.4%142.8%73.3%189.8%
Loss from operations
% of revenue-4.4%-42.8%26.7%-89.8%
Other income (expense)
Change in fair value of warrant liabilities
Gain/Loss on Investments—
Interest Expense
Non-Operating Income (Expense)
Total other income (expense)
Loss before income taxes
Income Tax Expense—
Net loss
% of revenue-5.0%-47.1%33.0%-95.1%
Earnings Per Share (Basic)
Earnings Per Share (Diluted)